Cargando…

Renoprotective effects of sucroferric oxyhydroxide in a rat model of chronic renal failure

INTRODUCTION: Sucroferric oxyhydroxide (PA21) is an efficacious, well-tolerated iron-based phosphate binder and a promising alternative to existing compounds. We compared the effects of PA21 with those of a conventional phosphate binder on renal function, mineral homeostasis and vascular calcificati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Neven, Ellen, Corremans, Raphaëlle, Vervaet, Benjamin A, Funk, Felix, Walpen, Sebastian, Behets, Geert J, D’Haese, Patrick C, Verhulst, Anja
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	ORIGINAL ARTICLES
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7538237/ https://www.ncbi.nlm.nih.gov/pubmed/33022710 http://dx.doi.org/10.1093/ndt/gfaa080

Ejemplares similares

Metformin and Canagliflozin Are Equally Renoprotective in Diabetic Kidney Disease but Have No Synergistic Effect
por: Corremans, Raphaëlle, et al.
Publicado: (2023)

Metformin: A Candidate Drug for Renal Diseases
por: Corremans, Raphaëlle, et al.
Publicado: (2018)

L-NAME Administration Enhances Diabetic Kidney Disease Development in an STZ/NAD Rat Model
por: Corremans, Raphaëlle, et al.
Publicado: (2021)

Preclinical Pharmacokinetics, Pharmacodynamics and Safety of Sucroferric  Oxyhydroxide
por: Cozzolino, Mario, et al.
Publicado: (2014)

Iron kinetics following treatment with sucroferric oxyhydroxide or ferric citrate in healthy rats and models of anaemia, iron overload or inflammation
por: Floege, Jürgen, et al.
Publicado: (2020)

Effects of sucroferric oxyhydroxide and sevelamer carbonate on chronic kidney disease–mineral bone disorder parameters in dialysis patients
por: Ketteler, Markus, et al.
Publicado: (2019)

The real-world effectiveness of sucroferric oxyhydroxide in European hemodialysis patients: a 1-year retrospective database analysis
por: Ramos, Rosa, et al.
Publicado: (2020)

Real-world safety and effectiveness of sucroferric oxyhydroxide for treatment of hyperphosphataemia in dialysis patients: a prospective observational study
por: Vervloet, Marc G, et al.
Publicado: (2021)

Phosphate binding by sucroferric oxyhydroxide ameliorates renal injury in the remnant kidney model
por: Nemoto, Yoshikazu, et al.
Publicado: (2019)

Iron-related parameters in dialysis patients treated with sucroferric oxyhydroxide
por: Covic, Adrian C., et al.
Publicado: (2017)

Efficacy and Safety of Sucroferric Oxyhydroxide and Calcium Carbonate in Hemodialysis Patients
por: Koiwa, Fumihiko, et al.
Publicado: (2017)

Evaluation of changes in ferritin levels during sucroferric oxyhydroxide treatment
por: Koiwa, Fumihiko, et al.
Publicado: (2018)

Sucroferric oxyhydroxide for hyperphosphatemia: a review of real-world evidence
por: Coyne, Daniel W., et al.
Publicado: (2022)

Impact of sucroferric oxyhydroxide on the oral and intestinal microbiome in hemodialysis patients
por: Abdelbary, Mohamed M. H., et al.
Publicado: (2022)

Sucroferric Oxyhydroxide in Maintenance Hemodialysis: A Retrospective, Comparative Cohort Study
por: Coyne, Daniel W., et al.
Publicado: (2020)

Real-world management of hyperphosphataemia with sucroferric oxyhydroxide: the VELREAL multicentre study
por: Navarro-González, Juan F, et al.
Publicado: (2021)

Safety and efficacy of sucroferric oxyhydroxide in pediatric patients with chronic kidney disease
por: Greenbaum, Larry A., et al.
Publicado: (2020)

Effects of Sucroferric Oxyhydroxide Compared to Lanthanum Carbonate and Sevelamer Carbonate on Phosphate Homeostasis and Vascular Calcifications in a Rat Model of Chronic Kidney Failure
por: Phan, Olivier, et al.
Publicado: (2015)

Bicarbonate levels in hemodialysis patients switching from lanthanum carbonate to sucroferric oxyhydroxide
por: Stavroulopoulos, Aristeidis, et al.
Publicado: (2018)

Unilateral Renal Ischemia-Reperfusion as a Robust Model for Acute to Chronic Kidney Injury in Mice
por: Le Clef, Nathalie, et al.
Publicado: (2016)

Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients
por: Floege, Jürgen, et al.
Publicado: (2015)

Environmental toxin-induced acute kidney injury
por: Vervaet, Benjamin A, et al.
Publicado: (2017)

A Magnesium Based Phosphate Binder Reduces Vascular Calcification without Affecting Bone in Chronic Renal Failure Rats
por: Neven, Ellen, et al.
Publicado: (2014)

Sucroferric oxyhydroxide decreases serum phosphorus level and fibroblast growth factor 23 and improves renal anemia in hemodialysis patients
por: Shima, Hisato, et al.
Publicado: (2018)

One-Year Historical Cohort Study of the Phosphate Binder Sucroferric Oxyhydroxide in Patients on Maintenance Hemodialysis
por: Kendrick, Jessica, et al.
Publicado: (2019)

Drug–drug interactions between sucroferric oxyhydroxide and losartan, furosemide, omeprazole, digoxin and warfarin in healthy subjects
por: Chong, Edward, et al.
Publicado: (2014)

Effectiveness of sucroferric oxyhydroxide in patients on on-line hemodiafiltration in real-world clinical practice: A retrospective study
por: Ferreira, Aníbal, et al.
Publicado: (2019)

Real-world effectiveness of sucroferric oxyhydroxide in patients on chronic hemodialysis: A retrospective analysis of pharmacy data
por: Coyne, Daniel W., et al.
Publicado: (2017)

Gut microbiome in hemodialysis patients treated with calcium acetate or treated with sucroferric oxyhydroxide: a pilot study
por: Merino-Ribas, Ana, et al.
Publicado: (2021)

Effect of the phosphate binder sucroferric oxyhydroxide in dialysis patients on endogenous calciprotein particles, inflammation, and vascular cells
por: Thiem, Ursula, et al.
Publicado: (2022)

Evaluation of Intestinal Phosphate Binding to Improve the Safety Profile of Oral Sodium Phosphate Bowel Cleansing
por: Robijn, Stef, et al.
Publicado: (2015)

Phosphate binder pill burden, adherence, and serum phosphorus control among hemodialysis patients converting to sucroferric oxyhydroxide
por: Gray, Kathryn, et al.
Publicado: (2019)

A 6-Month clinical practice pilot study of sucroferric oxyhydroxide on nutritional status in patients on peritoneal dialysis
por: Perez, Luis, et al.
Publicado: (2022)

Extracellular Nucleotides Regulate Arterial Calcification by Activating Both Independent and Dependent Purinergic Receptor Signaling Pathways
por: Opdebeeck, Britt, et al.
Publicado: (2020)

Sclerostin Protects Against Vascular Calcification Development in Mice
por: De Maré, Annelies, et al.
Publicado: (2022)

Proton pump inhibitors may hinder hypophosphatemic effect of lanthanum carbonate, but not of ferric citrate hydrate or sucroferric oxyhydroxide, in hemodialysis patients
por: Minakuchi, Hitoshi, et al.
Publicado: (2020)

A comparison between the combined effect of calcium carbonate with sucroferric oxyhydroxide and other phosphate binders: an in vitro and in vivo experimental study
por: Yaguchi, Atsushi, et al.
Publicado: (2019)

The effect of phosphate binder therapy with sucroferric oxyhydroxide on calcification propensity in chronic haemodialysis patients: a randomized, controlled, crossover trial
por: Thiem, Ursula, et al.
Publicado: (2020)

Management of hyperphosphatemia in patients with end-stage renal disease: focus on lanthanum carbonate
por: Persy, Veerle P, et al.
Publicado: (2009)

Circulating levels of sclerostin but not DKK1 associate with laboratory parameters of CKD-MBD
por: Behets, Geert J., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_1drtcgbhnneu4h67kmnata2t6n